ANDROPHY; ELLIOT J.

Patent Applications and Registrations

Patent applications and USPTO patent grants for ANDROPHY; ELLIOT J..The latest application filed is for "small molecule antiviral drug treatment for human papillomavirus infections".

Company Profile

2.13.15

ANDROPHY; ELLIOT J. - Indianapolis IN
Androphy; Elliot J. - Natick MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Small Molecule Antiviral Drug Treatment For Human Papillomavirus Infections App 20220142973 - ANDROPHY; ELLIOT J. ; et al.	2022-05-12
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20220090071 - Singh; Ravindra N. ; et al.	2022-03-24
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20190292540 - Singh; Ravindra N. ; et al.	2019-09-26
Combination therapies for treatment of spinal muscular atrophy Grant 10,420,753 - Androphy , et al. Sept	2019-09-24
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Grant 10,266,822 - Singh , et al.	2019-04-23
Combination Therapies For Treatment Of Spinal Muscular Atrophy App 20180235943 - Androphy; Elliot J. ; et al.	2018-08-23
Combination therapies for treatment of spinal muscular atrophy Grant 9,895,358 - Androphy , et al. February 20, 2	2018-02-20
Combination Therapies For Treatment Of Spinal Muscular Atrophy App 20170239225 - Androphy; Elliot J. ; et al.	2017-08-24
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20170096664 - Singh; Ravindra N. ; et al.	2017-04-06
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Grant 9,476,042 - Singh , et al. October 25, 2	2016-10-25
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20140066492 - SINGH; Ravindra N. ; et al.	2014-03-06
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Grant 8,586,559 - Singh , et al. November 19, 2	2013-11-19
Arylthiazolyl Piperidines And Related Compounds As Modulators Of Survival Motor Neuron (smn) Protein Production App 20130096160 - Marugan; Juan Jose ; et al.	2013-04-18
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20120165394 - SINGH; Ravindra N. ; et al.	2012-06-28
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Grant 8,110,560 - Singh , et al. February 7, 2	2012-02-07
Compounds For Treating Human Papillomavirus App 20110172311 - Androphy; Elliot J. ; et al.	2011-07-14
Compounds for treating human papillomavirus Grant 7,914,769 - Androphy , et al. March 29, 2	2011-03-29
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences Grant 7,838,657 - Singh , et al. November 23, 2	2010-11-23
Spinal Muscular Atrophy (sma) Treatment Via Targeting Of Smn2 Splice Site Inhibitory Sequences App 20100087511 - Singh; Ravindra N. ; et al.	2010-04-08
Spinal Muscular Atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences App 20070292408 - Singh; Ravindra N. ; et al.	2007-12-20
Diagnosis and treatment of cancer Grant 7,183,051 - Androphy , et al. February 27, 2	2007-02-27
Compounds for treating human papillomavirus App 20050250855 - Androphy, Elliot J. ; et al.	2005-11-10
Diagnosis and treatment of cancer App 20030082526 - Androphy, Elliot J. ; et al.	2003-05-01
Method for determining compound interaction with E2 binding proteins Grant 5,770,384 - Androphy , et al. June 23, 1	1998-06-23
Papillomavirus E2 trans-activation repressors Grant 5,616,559 - Androphy , et al. April 1, 1	1997-04-01
Papillomavirus E2 trans-activation repressors Grant 5,219,990 - Androphy , et al. June 15, 1	1993-06-15

Company Registrations

NCAGE Code	4BRA6	ANDROPHY ELLIOT J
CAGE Code	4BRA6	ANDROPHY, ELLIOT J

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.